Vertex Pharmaceuticals Inc. closed $45.72 below its 52-week high ($510.64), which the company achieved on August 1st.

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

This was the stock's second consecutive day of losses.

The FDA should have more big news for Vertex only a few weeks later. It expects to announce an approval decision on ...

The 12-month price targets, analyzed by analysts, offer insights with an average target of $508.38, a high estimate of ...

Investing in biotech stocks isn't for everyone. An unsuccessful clinical trial can cause a huge decline. The competition is ...

Kendric Cromer, 12, is among the first patients to be treated with gene therapy just approved by the F.D.A. that many other ...

Vertex Pharmaceuticals (VRTX) closed at $489.43 in the latest trading session, marking a +0.84% move from the prior day.

In a report released today, Brian Abrahams from RBC Capital maintained a Hold rating on Vertex Pharmaceuticals (VRTX – Research Report), ...

According to Benzinga Pro, Vertex Pharmaceuticals's peer group average for short interest as a percentage of float is 6.15%, ...

My name is Olivia Brayer. I'm a senior Biotech Analyst here at Cantor. And we're really excited to have the Vertex IR team with us. We have Susie Lisa who is Senior Vice President, and Manisha Pai, ...

Vertex Pharmaceuticals, a leader in Cystic Fibrosis treatment, reported strong financials in Q2 but faces limited growth in CF due to high market penetration. Despite a GAAP net loss in Q2 ...